- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
News
Article
Daily Derm Times: August 7, 2025
Author(s):
Key Takeaways
- BoNT-A combined with topical cream improves patient satisfaction and skin lightness compared to cream alone.
- Delgocitinib's approval in August 2025 follows successful DELTA 1, 2, and 3 clinical trials demonstrating efficacy and safety.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
Split-Face Study Reveals New Role for BoNT-A
Patients receiving BoNT-A plus topical cream reported greater satisfaction and better skin lightness than with cream alone.
Delgocitinib: Clinical Timeline and Approval
The drug’s approval in August 2025 follows robust efficacy and safety results from the DELTA 1, 2, and 3 clinical trials.
Time Equals Follicles: The Evolving Landscape of Hair Loss Treatment with Alan J. Bauman, MD
In this exclusive Q&A, Alan J. Bauman, MD, shares expert insights on innovative hair loss treatments, early intervention strategies, and the future of alopecia care.
Exploring Treatment Options Among Parents and Patients with Pediatric AD
Tina Bhutani, MD, MAS, discusses innovative pediatric atopic dermatitis treatments, including ruxolitinib cream, emphasizing collaborative decision-making for effective management.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
